New Product Launch Event of 'EVA-Pulsar&trade'
On March 2, 2024, Yongrenxin Medical's 'EVA-Pulsar&trade' new product launch event was held in Beijing. Under the joint witness of many well-known experts, investors, and entrepreneurs in various fields at home and abroad, Yongrenxin's latest generation of EVA-Pulsar&trade artificial heart (ventricular assist device) was grandly released.
This artificial heart combines advantages such as long-term implantation, ultra-small size, pulsating blood flow, high-flow assistance, and bionic coating, providing patients with a safer, more effective, and comfortable long-term cardiac assist. Moreover, EVA-Pulsar&trade has taken the lead in realizing a full-flow channel design in the industry, further enhancing the safety of artificial hearts and opening a new era for future artificial heart innovation.
Academician Hu Shengshou, Director of the National Center for Cardiovascular Diseases and Fuwai Hospital of the Chinese Academy of Medical Sciences, Professor Dong Nianguo from Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, President Yamazaki Junichi from the Japan Solar Medical Technology Research Institute, Managing Director of Weiwu Capital, Mr. Liu Weidong, Director of Yongrenxin Medical, and Ms. Yan Hua, Director and CEO of Yongrenxin Medical, jointly conducted the product launch.
Zhou Mingzi, Executive Director of Frost & Sullivan (Frost & Sullivan, abbreviated as 'Frost & Sullivan') Greater China, was invited to attend the event and released the '2024 China Heart Failure Device White Paper' at the event site, sharing new trends in artificial heart development with all parties attending and exploring the development of the artificial heart market.
Zhou Mingzi, Executive Director of Frost & Sullivan Greater China
In the white paper speech session, Zhou Mingzi shared a theme around heart failure devices in China. He mentioned that the large stockpile and high growth rate of the number of heart failure patients in China indicate that the patient group for heart failure will continue to expand in the future. Among them, left ventricular assist devices, as the main medical device for treating heart failure, receive the most market attention. In recent years, with the gradual promotion of related technologies, the public's awareness of products has gradually increased, the government and commercial medical security networks have extended their coverage, and more products have been approved for market launch, the entire market is expected to enter a stage of continuous growth.
Based on this background, Frost & Sullivan's research found that with the increasing willingness of doctors toapply heart failure devicesclinically, the payment ability of heart failure patients has also been continuously improving, and the national policy side has strongly supported the rapid development of ventricular assist devices. As a result, the number of heart transplantation surgeries in China has been continuously increasing, and the demand for long-term ventricular assist devices will also rise day by day. The artificial heart industry is expected to enter a long golden development era.
Zhou Mingzi also shared that according to Frost & Sullivan's research, from 2017 to 2021, the total number of heart failure patients globally showed an upward trend. Especially in China, the stockpile and high growth rate of the number of heart failure patients are significant. The local ventricular assist industry in China has just started, and facing such a huge patient population, the market space is vast. He mentioned that heart failure treatment devices can be mainly divided into three categories: mechanical assistance, electrical-related technology, and structural improvement. Their treatment principles are respectively to enhance the contractility of myocardium through mechanical support to improve the heart's pumping function, manage arrhythmias using electrophysiological technology, and repair or improve the heart structure through anatomical means. Among them, artificial hearts are a type of mechanical-assisted heart failure medical device.
Artificial hearts can be divided into two major categories according to function: ventricular assist devices and total artificial hearts. Although total artificial hearts can theoretically provide more comprehensive support, due to their relatively new technology, they are currently mainly limited to the research stage and have limited clinical application. Ventricular assist devices, after decades of development, have been widely used clinically globally.
Among these common ventricular assist devices, left ventricular assist devices are the most widely used. It guides blood from the left ventricle to the blood pump through an inlet blood vessel connected to the left ventricle, and then the blood pump pushes the blood into the aorta. This process effectively assists weakened ventricles, reduces the working load of the ventricles, and ensures that the needs for systemic blood circulation are met. This cutting-edge technology plays a crucial role in the treatment of end-stage heart failure patients. In the past 20 years, left ventricular assist devices have become an established treatment method for left heart failure.
The new generation of small blood pump EVA-Pulsar&trade> from Yongrenxin Medical was officially granted a medical device registration certificate by the National Medical Products Administration (NMPA) in 2024, becoming the fifth ventricular assist device blood pump to be launched in China. This product is also the second artificial heart approved for long-term implantation in China after the first generation EVAHEART (from Yongrenxin Medical). Compared with the first-generation product, the new generation ultra-small EVA-Pulsar&trade has been improved and upgraded in terms of system and design. While retaining advantages such as ultra-high flow and pulsating blood flow, the weight has been reduced to 260 grams and the volume has been reduced to 70%, achieving miniaturization and lightweighting of the blood pump and bringing revolutionary new features. The launch of Yongrenxin's new generation EVA-Pulsar is expected to further enhance Yongrenxin's competitiveness in the artificial heart market and further consolidate its market position in the field of artificial hearts. With continuous technological progress and market expansion, Yongrenxin Medical is expected to continue leading the development of the artificial heart industry in the future.
Currently, ventricular assist devices face challenges such as insufficient market competition, low device penetration rate due to adverse reactions and high prices, slow development due to insufficient medical resources, and high technical complexity and industry barriers that limit the number of entrants.
Facing these challenges, the artificial heart industry is driven by many factors such as doctor recognition, advancement of treatment timing, accelerated population aging, support from leading capital, and strong national policy support. In the future, with product technology iteration and upgrade, reduction in treatment prices, gradual accumulation of clinical experience, improvement in patient demand, awareness, and payment ability for heart failure treatment, it is believed that the left ventricular assist market will further grow.
